$NBIX News Banks, hedge funds and what Citi ha
Post# of 44829
Banks, hedge funds and what Citi has to tell its rich clients 7:47 a.m. Jan. 13, 2014 - Shawn Langlois
Stock futures gain as S&P 500 looks to halt skid 8:59 a.m. Jan. 7, 2014 - Victor Reklaitis
Yahoo, Palo Alto, Neurocrine are stocks to watch 5:31 a.m. Jan. 7, 2014 - Wallace Witkowski
Palo Alto, Convergys shares rise on acquisitions 5:08 p.m. Jan. 6, 2014 - Wallace Witkowski
Neurocrine Biosciences shares jump 60% on study 4:51 p.m. Jan. 6, 2014 - Wallace Witkowski
Neurocrine Biosciences shares surge on study 4:50 p.m. Jan. 6, 2014 - MarketWatch.com
S&P’s 50-day average remains the technical test 10:10 a.m. July 1, 2013 - Michael Ashbaugh
Volatility spike supports bullish market view 11:07 a.m. June 4, 2013 - Michael Ashbaugh
Volatility spike supports bullish market view 10:59 a.m. June 4, 2013 - Michael Ashbaugh
In focus: Bears trying to gain traction 6:30 p.m. May 29, 2013 - Lawrence G. McMillan
In focus: Awaiting the next move 7:57 p.m. Feb. 6, 2013 - Lawrence G. McMillan
Neurocrine to offer 9.5 mln shares 10:02 a.m. Jan. 19, 2012 - MarketWatch.com
Inspire, Questcor lead drug stocks north 2:55 p.m. April 5, 2011 - Val Brickates Kennedy
Neurocrine climbs on drug update 10:50 a.m. April 5, 2011 - Val Brickates Kennedy
Friday’s biggest gaining and declining stocks 4:31 p.m. Feb. 11, 2011 - Kate Gibson
Mannkind sinks in mixed drug sector 3:20 p.m. Feb. 11, 2011 - Val Brickates Kennedy
Drug stocks inch higher; Cytori slides 2:34 p.m. Oct. 8, 2010 - Val Brickates Kennedy
Neurocrine shares jump on analyst rating 9:07 a.m. Oct. 8, 2010 - Val Brickates Kennedy
Wednesday’s biggest gaining and declining stocks 4:26 p.m. Sept. 15, 2010 - MarketWatch
Neurocrine Biosciences shares up 4% 8:33 a.m. June 17, 2010 - Nick Godt
Seeking Alpha's Biotech Weekly: Gilead Rises With Phenex, Bass's Patent Attack, And More 4:00 p.m. Jan. 9, 2015 - Seeking Alpha
Neurocrine Biosciences Starts A Data-Rich Year On The Right Foot 11:37 a.m. Jan. 9, 2015 - Seeking Alpha
AbbVie Stock Down After Guidance, Downgrade 10:49 a.m. Jan. 9, 2015 - Investors Business Daily
Hottest Healthcare Stocks Now – SEM IPXL RDY ZLTQ 6:15 a.m. Jan. 9, 2015 - InvestorPlace.com
6 Serious Biotech and Health Care Movers 9:37 a.m. Jan. 8, 2015 - 247WallSt.com
Neurocrine Bio up on positive Phase 3 results 8:59 a.m. Jan. 8, 2015 - Seeking Alpha
Hottest Healthcare Stocks Now – NBIX IPXL HALO VRX 5:45 a.m. Jan. 8, 2015 - InvestorPlace.com
Hottest Healthcare Stocks Now – HALO NBIX AMAG ENDP 5:45 a.m. Jan. 7, 2015 - InvestorPlace.com
Our 3 Best Performing Stocks Of 2014 6:52 p.m. Jan. 5, 2015 - Seeking Alpha
15 Biotech Names For 2015 2:37 p.m. Jan. 5, 2015 - Seeking Alpha
What Investors Expect From Neurocrine Biosciences' Next Drug Announcement 1:53 p.m. Jan. 2, 2015 - benzinga.com
Biggest Movers in Healthcare Stocks Now – QGEN BABY ISRG REGN 12:45 p.m. Dec. 31, 2014 - InvestorPlace.com
Hottest Healthcare Stocks Now – ISIS NBIX CLDX EXAS 6:15 a.m. Dec. 26, 2014 - InvestorPlace.com
Commit To Buy Neurocrine Biosciences At $17, Earn 30.2% Annualized Using Options 12:18 p.m. Dec. 24, 2014 - TheStreet.com
5 Stocks With Ugly Operating Margin Growth — NBIX CTEL TSRA NYNY PMFG 2:15 a.m. Dec. 22, 2014 - InvestorPlace.com
Biggest Movers in Healthcare Stocks Now – NLNK MACK ELGX HZNP 3:00 p.m. Dec. 19, 2014 - InvestorPlace.com
2015 Biotech Drug/Stock Outlook: Here's What You Need to Know 9:20 a.m. Dec. 17, 2014 - TheStreet.com
Auspex Drug Reduces Uncontrolled Movements in Huntington's Patients 4:06 p.m. Dec. 16, 2014 - TheStreet.com
5 Stocks With Poor Operating Margin Growth — NBIX CTEL TSRA NYNY PMFG 2:00 a.m. Dec. 15, 2014 - InvestorPlace.com
Biggest Movers in Healthcare Stocks Now – NBIX TECH AZN ISIS 7:30 a.m. Dec. 10, 2014 - InvestorPlace.com
Critical Alerts For Zynga, Neurocrine Biosciences, Yum! Brands, eBay and TrueCar Released By InvestorsObserver 9:31 a.m. Jan. 9, 2015 - PR Newswire - PRF
Neurocrine Biosciences to Present at the 33rd Annual J.P. Morgan Healthcare Conference 1:00 p.m. Jan. 8, 2015 - PR Newswire - PRF
AbbVie Announces Positive Top-Line Results From Phase 3 Study of Investigational Medicine Elagolix in Patients with Endometriosis 8:00 a.m. Jan. 8, 2015 - PR Newswire - PRF
Biotech Equities Update - Biogen Idec, ACADIA Pharma, Halozyme Therapeutics, Neurocrine Biosciences, and Bluebird Bio 8:50 a.m. Dec. 12, 2014 - PR Newswire - PRF
Just Released: New Research on American Airlines, Staples, Cyren, Neurocrine Biosciences, and Cherokee 9:17 a.m. Dec. 11, 2014 - PR Newswire - PRF
Neurocrine Biosciences Announces Expansion of its Clinical Pipeline 8:00 a.m. Dec. 10, 2014 - PR Newswire - PRF
Neurocrine Biosciences to Present at the 25th Annual Oppenheimer Healthcare Conference 7:00 p.m. Dec. 4, 2014 - PR Newswire - PRF
Neurocrine to Present at the 2014 Deutsche Bank BioFEST and the 26th Annual Piper Jaffray Healthcare Conference 1:00 p.m. Nov. 25, 2014 - PR Newswire - PRF
Retrophin Names Margaret Valeur-Jensen, Ph.D. as General Counsel 8:01 a.m. Nov. 19, 2014 - BusinessWire - BZX
Neurocrine Biosciences to Present at the Jefferies 2014 Global Healthcare Conference 1:56 p.m. Nov. 12, 2014 - PR Newswire - PRF
Neurocrine Biosciences to Present at the Jefferies 2014 Global Healthcare Conference 1:00 p.m. Nov. 12, 2014 - PR Newswire - PRF
Neurocrine Biosciences, Inc. Announces Appointment of Darin Lippoldt as Chief Legal Officer 7:30 a.m. Nov. 4, 2014 - PR Newswire - PRF
Neurocrine Biosciences to Present at the Nomura Biotechnology Conference 7:00 p.m. Nov. 3, 2014 - PR Newswire - PRF
Neurocrine Biosciences Reports Third Quarter 2014 Results 4:01 p.m. Nov. 3, 2014 - PR Newswire - PRF
Neurocrine Biosciences Receives Breakthrough Therapy Designation for NBI-98854 in Tardive Dyskinesia 6:30 a.m. Oct. 30, 2014 - PR Newswire - PRF
Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2014 Financial Results 3:05 p.m. Oct. 27, 2014 - PR Newswire - PRF
Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 7:35 a.m. Oct. 27, 2014 - PR Newswire - PRF
Neurocrine Announces Initiation Of Phase III Study For VMAT2 Inhibitor NBI-98854 3:05 p.m. Oct. 20, 2014 - PR Newswire - PRF
Neurocrine Announces Expansion Of VMAT2 Inhibitor Program With Initiation Of Tourette Syndrome Clinical Study 3:02 p.m. Oct. 2, 2014 - PR Newswire - PRF
Neurocrine Biosciences, Inc. Announces Appointment of Malcolm Lloyd-Smith as Chief Regulatory Officer 4:20 p.m. Oct. 1, 2014 - PR Newswire - PRF